David J. FitzGerald

7.3k citations

70 papers · 5.9k indexed · 1 hit paper · h-index 37

Immunology top 0.5%
Molecular Biology top 5%
Biotechnology top 0.1%
Radiology, Nuclear Medicine and Imaging top 0.5%
Oncology top 2%

Co-authors: Ira Pastan Robert J. Kreitman Vijay K. Chaudhary Mark C. Willingham Maryalice Stetler‐Stevenson Wyndham H. Wilson Raffit Hassan Thomas A. Waldmann
Topics: Toxin Mechanisms and Immunotoxins (56 papers)Transgenic Plants and Applications (40 papers)Monoclonal and Polyclonal Antibodies Research (19 papers)
Cited by: Biotechnology Immunology Radiology, Nuclear Medicine and Imaging
Journals: Nature New England Journal of Medicine Cell
Partner nations: United States United Kingdom Poland

In The Last Decade

David J. FitzGerald

70 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

2012 440 citations Maryalice Stetler‐Stevenson, Ira Pastan et al. profile →

Peers

Countries citing papers authored by David J. FitzGerald

Since Specialization

Citations

This map shows the geographic impact of David J. FitzGerald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. FitzGerald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. FitzGerald more than expected).

Fields of papers citing papers by David J. FitzGerald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. FitzGerald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. FitzGerald. The network helps show where David J. FitzGerald may publish in the future.

Co-authorship network of co-authors of David J. FitzGerald

This figure shows the co-authorship network connecting the top 25 collaborators of David J. FitzGerald. A scholar is included among the top collaborators of David J. FitzGerald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. FitzGerald. David J. FitzGerald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins 2017 ·Oncogene ·Antonella Antignani,David Segal,Nathan C. Simon,Robert J. Kreitman,David C.S. Huang,David J. FitzGerald	11
2	Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1 2016 ·Cancer Research ·(unknown),David J. FitzGerald,Scott E. Martin,Paresma Patel,Marco Prunotto,Pinar Ormanoglu,Craig J. Thomas,Ira Pastan	15
3	Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors 2013 ·Molecular Cancer Therapeutics ·Xiufen Liu,Laiman Xiang,David J. FitzGerald,Ira Pastan	13
4	Combining the Antimesothelin Immunotoxin SS1P With the BH3-mimetic ABT-737 Induces Cell Death in SS1P-resistant Pancreatic Cancer Cells 2013 ·Journal of Immunotherapy ·Kevin Hollevoet,Antonella Antignani,David J. FitzGerald,Ira Pastan	15
5	Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy 2012 ·Proceedings of the National Academy of Sciences ·Hui Wei,Laiman Xiang,Alan S. Wayne,Oleg Chertov,David J. FitzGerald,Tapan K. Bera,Ira Pastan	42
6	Combination treatments with ABT‐263 and an immunotoxin produce synergistic killing of ABT‐263‐resistant small cell lung cancer cell lines 2012 ·International Journal of Cancer ·Abid R. Mattoo,David J. FitzGerald	27
7	Proteolytic Cleavage of a C-terminal Prosequence, Leading to Autoprocessing at the N Terminus, Activates Leucine Aminopeptidase from Pseudomonas aeruginosa 2009 ·Journal of Biological Chemistry ·(unknown),Jennifer C. Rea,(unknown),Ralf Hertle,(unknown),Antonella Antignani,Diana V. Pastrana,David J. FitzGerald	19
8	Approach to the patient after relapse of hairy cell leukemia 2009 ·Leukemia & lymphoma ·Robert J. Kreitman,David J. FitzGerald,Ira Pastan	7
9	A nonradioactive, cell-free method for measuring protein synthesis inhibition by Pseudomonas exotoxin 2006 ·Analytical Biochemistry ·Diana V. Pastrana,David J. FitzGerald	8
10	Immunotoxin therapy of cancer 2006 ·Nature reviews. Cancer ·Ira Pastan,Raffit Hassan,David J. FitzGerald,Robert J. Kreitman	414
11	Small RNA Regulators and the Bacterial Response to Stress 2006 ·Cold Spring Harbor Symposia on Quantitative Biology ·Susan Gottesman,Colleen A. McCullen,Maude Guillier,Carin K. Vanderpool,Nadim Majdalani,Jihane N. Benhammou,Karl M. Thompson,Peter Fitzgerald,Nathaniel A. Sowa,David J. FitzGerald	192
12	Identification of tandem duplicate regulatory small RNAs in Pseudomonas aeruginosa involved in iron homeostasis 2004 ·Proceedings of the National Academy of Sciences ·Paula J. Wilderman,Nathaniel A. Sowa,David J. FitzGerald,Peter Fitzgerald,Susan Gottesman,Urs A. Ochsner,Michael L. Vasil	348
13	Recombinant immunotoxins for treating cancer 2004 ·International Journal of Medical Microbiology ·David J. FitzGerald,Robert J. Kreitman,Wyndham H. Wilson,David Squires,Ira Pastan	68
14	Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia 2001 ·New England Journal of Medicine ·Robert J. Kreitman,Wyndham H. Wilson,(unknown),(unknown),Maryalice Stetler‐Stevenson,David J. FitzGerald,Ira Pastan	387
15	Sensitivity of human acute myeloid leukaemia to diphtheria toxin‐GM‐CSF fusion protein 1997 ·British Journal of Haematology ·Henk Rozemuller,Elwin Rombouts,Ivo P. Touw,David J. FitzGerald,Robert J. Kreitman,Ira Pastan,Anton Hagenbeek,Anton C. Martens	5
16	Single-chain immunotoxin fusions between anti-tac and Pseudomonas exotoxin: Relative importance of the two toxin disulfide bonds 1993 ·Bioconjugate Chemistry ·R. J. Kreitman,Janendra K. Batra,Saraswathy Seetharam,Vijay K. Chaudhary,David J. FitzGerald,I Pastan	64
17	Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol 1992 ·Biochemistry ·Trevor I. Prior,David J. FitzGerald,Ira Pastan	41
18	A proper amino terminus of diphtheria toxin is important for cytotoxicity 1991 ·Biochemical and Biophysical Research Communications ·Vijay K. Chaudhary,David J. FitzGerald,Ira Pastan	32
19	Use of Pseudomonas aeruginosa Toxin A in the Construction of Conjugate Vaccines and Immunotoxins 1987 ·Clinical Infectious Diseases ·Stanley J. Cryz,(unknown),Jerald Sadoff,R. Germanier,Ira Pastan,Mark C. Willingham,David J. FitzGerald	11
20	Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. 1985 ·PubMed ·Robert Pirker,David J. FitzGerald,Thomas C. Hamilton,Robert F. Ozols,Mark C. Willingham,Ira Pastan	77

About David J. FitzGerald

David J. FitzGerald is a scholar working on Biotechnology, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 70 papers that have together received 5.9k indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (56 papers), Transgenic Plants and Applications (40 papers) and Monoclonal and Polyclonal Antibodies Research (19 papers). The work is most often cited by research in Biotechnology (1.8k citations), Immunology (3.4k citations) and Radiology, Nuclear Medicine and Imaging (1.5k citations). David J. FitzGerald has collaborated with scholars based in United States, United Kingdom and Poland. Frequent co-authors include Ira Pastan, Robert J. Kreitman, Vijay K. Chaudhary, Mark C. Willingham, Maryalice Stetler‐Stevenson, Wyndham H. Wilson, Raffit Hassan, Ira Pastan, Thomas A. Waldmann and Alan S. Wayne. Their work appears in journals such as Nature, New England Journal of Medicine and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact